Author + information
- S1936879815020646-928c8a01bf5e9d1c65802ac3eacf45d7Haitham Abu Sharar,
- S1936879815020646-59cbc15db590596d683979732acfd436Hugo A. Katus and
- S1936879815020646-37b1cd6e304d614b995bb44e15526827Raffi Bekeredjian
Compared to first generation drug eluting stents (DES), second generation DES show a significant improvement in various clinical endpoints. The evolution of newer coronary stent systems has now progressed towards design modifications with improved interventional Performance and clinical outcomes. The SYNERGYTM stent (Boston Scientific Corp., Natick, Massachusetts) represents a new DES generation with reduced strut thickness and only abluminal polymer coating aiming at improved deliverability.
In this single center study, patients were included upon receiving an attempted SYNERGYTM stent implantation in the time from February 2013 to June 2015 as a bail-out strategy after failed implantation of a second generation DES (Promus ElementTM, Boston Scientific, Natick, Massachusetts, Xience PrimeTM, Abbott Vascular, Santa Clara, California, Resolute IntegrityTM, Medtronic, Santa Rosa, California) in complex coronary lesions, which were categorized through ACC/AHA classification and SYNTAX Score.
The study population consisted of 97 patients with attempted bail-out SYNERGYTM stent implantation, which was successful in 89 (91.8%) cases. ACC/AHA classification showed mostly complex target coronary lesions: A 1.0%, B1 1.0%, B2 17.5%, C1 22.7%, C2 57.7%. The SYNTAX Score classified the patients into low (9.1%), intermediate (23.4%) and high (67.5%) risk categories.
The SYNERGYTM stent has demonstrated remarkable deliverability to different complex coronary artery lesion subsets, highlighting an enhanced interventional stent performance and its usefulness as a drug-eluting bail-out stent.